- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07621783
Leucine-rich α2-glycoprotein Correlation With Clinical, Endoscopic and Histological Disease Activity of IBD in a EuRopean Context (LEADER)
May 29, 2026 updated by: Imelda GI Clinical Research Center
Leucine-rich α2-glycoprotein Correlation With Clinical, Endoscopic and Histological Disease Activity of IBD in a EuRopean Context: LEADER Trial.
Prospectively study the correlation between Leucine-rich α2-glycoprotein (LRG) and clinical/endoscopic/histological disease activity in patients with inflammatory bowel disease (IBD) in Europe.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
100
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Peter Bossuyt
- Phone Number: MD PhD
- Email: peter.bossuyt@imelda.be
Study Locations
-
-
-
Bonheiden, Belgium, 2820
- Recruiting
- Imelda General Hospital
-
Contact:
- Peter Bossuyt, MD PhD
- Phone Number: +3215505691
- Email: peter.bossuyt@imelda.be
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Probability Sample
Study Population
patients with IBD
Description
Inclusion Criteria:
- ≥18 years
- Patient with confirmed diagnosis of IBD
- Patient with planned endoscopy (ileocolonoscopy for Crohn's disease (CD)/ulcerative colitis (UC) or sigmoidoscopy for UC) for the assessment of endoscopic disease activity according to routine practice
- willing to provide informed consent
Exclusion Criteria:
- Patient with IBD unspecified
- Patient with ileo- or colostomy
- Patient with total colectomy
- Women that are pregnant
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
patient with IBD
patient with Crohn or ulcerative colitis
|
Leucine-rich α2-glycoprotein measurement
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Correlation between LRG serum level and endoscopic disease activity in CD and UC
Time Frame: Day 1
|
Correlation between LRG serum level and endoscopic disease activity in CD and UC
|
Day 1
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 1, 2026
Primary Completion (Estimated)
December 31, 2026
Study Completion (Estimated)
December 31, 2026
Study Registration Dates
First Submitted
May 24, 2026
First Submitted That Met QC Criteria
May 29, 2026
First Posted (Actual)
June 2, 2026
Study Record Updates
Last Update Posted (Actual)
June 2, 2026
Last Update Submitted That Met QC Criteria
May 29, 2026
Last Verified
May 1, 2026
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- imelda202601
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Crohn Disease (CD)
-
Direct Biologics, LLCNot yet recruiting
-
University Hospital, GrenobleNot yet recruiting
-
Groupe d'Etude Therapeutique des Affections Inflammatoires...RecruitingCrohn Disease (CD)France
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityRecruiting
-
Alimentiv Inc.The Leona M. and Harry B. Helmsley Charitable Trust; Horizon Europe; Stichting...RecruitingCrohn Disease (CD)Netherlands, Belgium, Italy, United Kingdom, Slovenia
-
San Giovanni Addolorata HospitalUniversity of Roma La SapienzaNot yet recruiting
-
Ana Maldonado-ContrerasRecruiting
-
Second Affiliated Hospital of Wenzhou Medical UniversityCompleted
-
University Hospital, Clermont-FerrandNot yet recruiting
-
Central Hospital, Nancy, FranceNot yet recruitingCrohn Disease (CD)France
Clinical Trials on Leucine-rich α2-glycoprotein
-
Benha UniversityCompletedAcne Vulgaris | Probiotic | Influence | Serum Leucine-Rich Alpha-2 Glycoprotein 1Egypt
-
Showa Inan General HospitalRecruiting
-
University Hospital, Clermont-FerrandCompletedMetabolic Syndrome | Predisposition to Cardiovascular DiseaseFrance